Vimarsana
Biggest News Aggregation in the World

Roche Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roche Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roche Inc Today - Breaking & Trending Today

Critical Contrast: Biogen (NASDAQ:BIIB) and Poseida Therapeutics (NASDAQ:PSTX) - Vimarsana News

Critical Contrast: Biogen (NASDAQ:BIIB) and Poseida Therapeutics (NASDAQ:PSTX)

Biogen (NASDAQ:BIIB – Get Free Report) and Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Profitability This table compares Biogen and Poseida Therapeutics’ net […]

Do Patent Claims to Methods of Treatment Cover In Vivo Transformations? | Mintz - Intellectual Property Viewpoints - Vimarsana News

Do Patent Claims to Methods of Treatment Cover In Vivo Transformations? | Mintz - Intellectual Property Viewpoints

Where an alleged infringer administers a substance A to a subject, and the substance is subsequently transformed to a therapeutic agent X inside the subject’s body, does the...

Reviewing Poseida Therapeutics (NASDAQ:PSTX) and AIM ImmunoTech (NYSE:AIM) - Vimarsana News

Reviewing Poseida Therapeutics (NASDAQ:PSTX) and AIM ImmunoTech (NYSE:AIM)

AIM ImmunoTech (NYSE:AIM – Get Free Report) and Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation. Insider and Institutional Ownership 12.8% of AIM […]

Source: wkrb13.com
Husker research duo selected as Phase 1 winners in the NIH's Targeted Genome Editor Delivery Challenge - Vimarsana News

Husker research duo selected as Phase 1 winners in the NIH's Targeted Genome Editor Delivery Challenge

A Husker research duo was named a first-round winner in a National Institutes of Health competition aimed at generating solutions for delivering genome-editing technology to the cells of people with rare and common diseases.

AIM ImmunoTech (NYSE:AIM) versus Poseida Therapeutics (NASDAQ:PSTX) Critical Survey - Vimarsana News

AIM ImmunoTech (NYSE:AIM) versus Poseida Therapeutics (NASDAQ:PSTX) Critical Survey

AIM ImmunoTech (NYSE:AIM – Get Free Report) and Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations. Earnings & Valuation This table compares AIM […]